Moderna Inc
MRNA27.480USD
-0.125-0.45%
交易中 （美東）報價延遲15分鐘
10.69B總市值
虧損本益比TTM
關於 Moderna Inc 公司
Moderna, Inc. 是一家生物技術公司。該公司正在開發一種由信使核糖核酸 (mRNA) 製成的新藥。該公司正在獨立或與戰略合作伙伴一起開發用於傳染病、免疫腫瘤學、罕見疾病和自身免疫性疾病的療法和疫苗。mRNA 藥物旨在引導人體細胞產生具有治療或預防益處的細胞內、膜或分泌蛋白，並有可能治療一系列疾病。其多樣化的開發渠道包括 45 個治療和疫苗項目，其中 9 個處於後期開發階段。其產品包括 COVID-19 疫苗（mRNA-1273/Spikevax、下一代 mRNA-1283）、RSV 疫苗（mRNA-1345）、季節性流感疫苗（mRNA-1010、mRNA-1011、mRNA-1012、mRNA-1020 和 mRNA-1030）、聯合疫苗（mRNA-1083、mRNA-1230、mRNA-1045 和 mRNA-1365）、CMV 疫苗（mRNA-1647）、EBV 疫苗（mRNA-1189 和 mRNA-1195）等。
公司簡介
公司代碼MRNA
公司名稱Moderna Inc
上市日期Dec 07, 2018
CEOMr. Stephane Bancel
員工數量5800
證券類型Ordinary Share
年結日Dec 07
公司地址325 Binney Street
城市CAMBRIDGE
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編02142
電話16177146500
網址https://www.modernatx.com/
公司代碼MRNA
上市日期Dec 07, 2018
CEOMr. Stephane Bancel
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Stephen Hoge, M.D.
Dr. Stephen Hoge, M.D.
President
President
1.61M
+0.09%
Mr. Paul Sagan
Mr. Paul Sagan
Independent Director
Independent Director
494.13K
+6.84%
Ms. Shannon Thyme Klinger
Ms. Shannon Thyme Klinger
Corporate Secretary, Chief Legal Officer
Corporate Secretary, Chief Legal Officer
26.89K
+2.24%
Mr. James M. Mock
Mr. James M. Mock
Chief Financial Officer
Chief Financial Officer
16.94K
+4.63%
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Independent Director
Independent Director
3.08K
+46.51%
Tallett (Elizabeth E)
Tallett (Elizabeth E)
Independent Director
Independent Director
703.00
--
Dr. Noubar B. Afeyan, Ph.D.
Dr. Noubar B. Afeyan, Ph.D.
Non-Executive Independent Chairman of the Board, Co-Founder
Non-Executive Independent Chairman of the Board, Co-Founder
--
--
Dr. Rose Loughlin
Dr. Rose Loughlin
Executive Vice President - Research
Executive Vice President - Research
--
--
Mr. Jerh Collins
Mr. Jerh Collins
Chief Technical Operations and Quality Officer
Chief Technical Operations and Quality Officer
--
--
Mr. Stephane Bancel
Mr. Stephane Bancel
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Stephen Hoge, M.D.
Dr. Stephen Hoge, M.D.
President
President
1.61M
+0.09%
Mr. Paul Sagan
Mr. Paul Sagan
Independent Director
Independent Director
494.13K
+6.84%
Ms. Shannon Thyme Klinger
Ms. Shannon Thyme Klinger
Corporate Secretary, Chief Legal Officer
Corporate Secretary, Chief Legal Officer
26.89K
+2.24%
Mr. James M. Mock
Mr. James M. Mock
Chief Financial Officer
Chief Financial Officer
16.94K
+4.63%
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Independent Director
Independent Director
3.08K
+46.51%
Tallett (Elizabeth E)
Tallett (Elizabeth E)
Independent Director
Independent Director
703.00
--
收入明細
單位: USD更新時間: 7月6日 週日
單位: USD更新時間: 7月6日 週日
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
業務USD
名稱
營收
佔比
COVID
84.00M
97.67%
RSV
2.00M
2.33%
地區USD
名稱
營收
佔比
Rest of the World
55.00M
63.95%
United States
31.00M
36.05%
Europe
0.00
0.00%
業務
地區
業務USD
名稱
營收
佔比
COVID
84.00M
97.67%
RSV
2.00M
2.33%
股東統計
更新時間: 5月17日 週六
更新時間: 5月17日 週六
持股股東
股東類型
持股股東
持股股東
佔比
The Vanguard Group, Inc.
10.41%
Baillie Gifford & Co.
6.45%
Fidelity Management & Research Company LLC
5.39%
BlackRock Institutional Trust Company, N.A.
4.62%
State Street Global Advisors (US)
4.60%
Other
68.54%
持股股東
持股股東
佔比
The Vanguard Group, Inc.
10.41%
Baillie Gifford & Co.
6.45%
Fidelity Management & Research Company LLC
5.39%
BlackRock Institutional Trust Company, N.A.
4.62%
State Street Global Advisors (US)
4.60%
Other
68.54%
股東類型
持股股東
佔比
Investment Advisor
40.95%
Investment Advisor/Hedge Fund
14.84%
Hedge Fund
7.44%
Corporation
4.68%
Research Firm
4.41%
Individual Investor
2.56%
Bank and Trust
2.41%
Pension Fund
1.26%
Venture Capital
1.21%
Other
20.25%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
2012
312.35M
80.76%
-23.80M
2025Q1
2127
325.75M
84.24%
-21.87M
2024Q4
2176
321.41M
83.21%
-6.67M
2024Q3
2154
311.92M
81.18%
-17.40M
2024Q2
2186
316.03M
82.47%
-13.47M
2024Q1
2203
318.24M
83.12%
-1.14M
2023Q4
2309
311.40M
81.63%
+3.41M
2023Q3
2445
301.25M
79.05%
-6.86M
2023Q2
2461
301.15M
78.90%
-7.01M
2023Q1
2466
303.08M
78.58%
-1.88M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
The Vanguard Group, Inc.
40.25M
10.41%
+71.93K
+0.18%
Mar 31, 2025
Baillie Gifford & Co.
24.95M
6.45%
-13.94M
-35.85%
Mar 31, 2025
Fidelity Management & Research Company LLC
20.83M
5.39%
+2.44M
+13.30%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
17.87M
4.62%
-166.51K
-0.92%
Mar 31, 2025
State Street Global Advisors (US)
17.78M
4.6%
+201.32K
+1.15%
Mar 31, 2025
Boston Biotech Ventures, L.L.C.
9.21M
2.38%
+160.31K
+1.77%
Mar 05, 2025
Two Sigma Investments, LP
8.26M
2.14%
+7.49M
+976.22%
Mar 31, 2025
Geode Capital Management, L.L.C.
7.46M
1.93%
+215.24K
+2.97%
Mar 31, 2025
Theleme Partners LLP
7.24M
1.87%
-64.47K
-0.88%
Mar 31, 2025
OCHA, L.L.C.
6.56M
1.7%
--
--
Mar 05, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
iShares Genomics Immunology and Healthcare ETF
4.09%
Global X Genomics & Biotechnology ETF
4.08%
First Trust NYSE Arca Biotechnology Index Fund
3.31%
SPDR S&P Biotech ETF
2.42%
VanEck Biotech ETF
2.35%
Virtus LifeSci Biotech Products ETF
1.94%
Langar Global HealthTech ETF
1.9%
WisdomTree BioRevolution Fund
1.66%
Invesco S&P 500 Equal Weight Health Care ETF
1.65%
ROBO Global Healthcare Technology & Innovation ETF
1.43%
查看更多
iShares Genomics Immunology and Healthcare ETF
佔比4.09%
Global X Genomics & Biotechnology ETF
佔比4.08%
First Trust NYSE Arca Biotechnology Index Fund
佔比3.31%
SPDR S&P Biotech ETF
佔比2.42%
VanEck Biotech ETF
佔比2.35%
Virtus LifeSci Biotech Products ETF
佔比1.94%
Langar Global HealthTech ETF
佔比1.9%
WisdomTree BioRevolution Fund
佔比1.66%
Invesco S&P 500 Equal Weight Health Care ETF
佔比1.65%
ROBO Global Healthcare Technology & Innovation ETF
佔比1.43%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
